Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Trip.com Group Ltd — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Trip.com Group Ltd trades at $39.2 (market cap $24.60B). The key difference: Trip.com Group Ltd is far larger — about 3.3× Spyre Therapeutics Inc. Common Stock's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Trip.com Group Ltd for 80 Days on average.
| SYRE | TCOM | |
|---|---|---|
Market Cap | $7.52B | $24.60B |
Volume | 1,441,031 | 1,981,955 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $78.96 |
52-Week Low | $22.18 | $37.96 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $6.52B | $16.75B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TCOM trades at $38.88, up 0.31% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 7.48, net income margin of 36.9%, and robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Recent Q2 2026 earnings beat expectations at $1.07 per share, though Q1 and Q4 2025 missed. Cash flow remains positive with $7.11B net cash flow in 2024, and the balance sheet is healthy with total assets of $242.58B and debt-to-asset ratio improving to 16.37%.
The outlook is mixed: analyst consensus is bullish with a $56.64 price target and 70.45% buy ratings, but regulatory risks and recent antitrust fines pose challenges. Earnings growth and international expansion are key catalysts, yet competition and market volatility require caution. The stock presents value given low valuations, but investors must weigh regulatory headwinds against fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
